Kite, A Gilead Company
Kite is dedicated to achieving cures with cell therapy, focusing on harnessing the immune system to target and attack cancer. They develop personalized CAR T-cell therapies for blood cancers, with a broad pipeline of research and development efforts to improve patient responses and manufacturing speed.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Products
Autologous CAR T‑cell therapies for hematologic malignancies
One‑time autologous cellular immunotherapies manufactured from a patient’s own T cells, genetically modified to target certain types of blood cancer and returned to the same patient.
Autologous CAR T‑cell therapies for hematologic malignancies
One‑time autologous cellular immunotherapies manufactured from a patient’s own T cells, genetically modified to target certain types of blood cancer and returned to the same patient.
Services
Clinical‑grade manufacturing and scale‑up services to produce patient‑derived CAR T cell products for investigational and commercial use.
Design, conduct, and management of clinical studies and programs to provide investigational therapies outside of clinical trials.
Partnerships and external research funding to support preclinical and clinical development of cell therapy approaches.
Medical information support and processes for reporting suspected adverse events and product complaints to healthcare professionals and regulators.
Clinical‑grade manufacturing and scale‑up services to produce patient‑derived CAR T cell products for investigational and commercial use.
Design, conduct, and management of clinical studies and programs to provide investigational therapies outside of clinical trials.
Partnerships and external research funding to support preclinical and clinical development of cell therapy approaches.
Medical information support and processes for reporting suspected adverse events and product complaints to healthcare professionals and regulators.
Expertise Areas
- Cell therapy development
- CAR T‑cell manufacturing
- Clinical trial management and expanded access
- Regulatory affairs and agency interactions
Key Technologies
- CAR T‑cell therapy (autologous)
- T‑cell genetic engineering (CAR insertion)
- Ex vivo cell expansion and bioreactors
- GMP cell therapy manufacturing